ijms-logo

Journal Browser

Journal Browser

Molecular Mechanism of Leukemogenesis

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 909

Special Issue Editor


E-Mail Website
Guest Editor
Laboratorio de Genética Funcional del Cáncer, Instituto Nacional de Medicina Genómica (INMEGEN) & Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico
Interests: acute myeloid leukemia; leukemogenesis; epigenetics; transcription factor; oncoprotein; signal transduction; cell cycle; novel strategies; targeted therapy; apoptosis; apoptosis rate; article; biogenesis; bioinformatics; cell count; cell proliferation; controlled study; flow cytometry; genetic transfection; human; human cell; human tissue; liquid chromatography-mass spectrometry; major clinical study; mass spectrometry; northern blotting; protein expression; protein function; protein synthesis; proteomics; real time polymerase chain reaction; real time reverse transcription polymerase chain reaction; RNA sequencing; RNA translation; transcriptome sequencing; western blotting; B cell acute lymphoblastic leukemia; carcinogenesis; child; chromosome analysis; copy number variation; cytogenetics; DNA extraction; female; follow up; gene fusion; gene mutation; gene rearrangement; high throughput sequencing; immunophenotyping; infant; leukocyte count; male; microarray analysis; minimal residual

Special Issue Information

Dear Colleagues,

Leukemias have been the spearhead of our understanding of how cancer develops. Leukemias are one of the diseases for which great leaps have been made in the development of specific treatments; through this precision medicine, we have transitioned from 0% survival in the last 80 years to almost 90% survival in some childhood leukemias. In the case of leukemias, many of the molecular mechanisms related to their development are mechanisms related to treatment and mechanisms that will allow us to understand the development of other cancers. The molecular mechanisms related to the origin of these neoplasms allow us to understand the degree to which they progress from pre-leukemic states such as myelodysplastic syndromes to the final development of leukemias. But these mechanisms are also present in children with Down's syndrome, which has allowed us to understand the progression from a transient dysmelopoiesis syndrome of the newborn to the development of leukemia. The approach of molecular mechanisms in leukemiogenesis will allow us to better understand this pathology in order to design targeted prevention strategies and advances in precision medicine for this pathology to further increase the survival of patients suffering from these pathologies.

Dr. Juan Manuel Mejia-Arangure
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • leukemias
  • molecular mechanisms
  • leukemiogenesis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2625 KiB  
Article
Targeting USP14/UCHL5: A Breakthrough Approach to Overcoming Treatment-Resistant FLT3-ITD-Positive AML
by Ayako Nogami, Hideki Jose Amemiya, Hiroki Fujiwara, Yoshihiro Umezawa, Shuji Tohda and Toshikage Nagao
Int. J. Mol. Sci. 2024, 25(19), 10372; https://doi.org/10.3390/ijms251910372 - 26 Sep 2024
Viewed by 671
Abstract
FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations in acute myeloid leukemia (AML) are associated with poor prognosis and therapy resistance. This study aimed to demonstrate that inhibiting the deubiquitinating enzymes ubiquitin-specific peptidase 14 (USP14) and ubiquitin C-terminal hydrolase L5 (UCHL5) [...] Read more.
FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations in acute myeloid leukemia (AML) are associated with poor prognosis and therapy resistance. This study aimed to demonstrate that inhibiting the deubiquitinating enzymes ubiquitin-specific peptidase 14 (USP14) and ubiquitin C-terminal hydrolase L5 (UCHL5) (USP14/UCHL5) with b-AP15 or the organogold compound auranofin (AUR) induces apoptosis in the ITD-transformed human leukemia cell line MV4-11 and mononuclear leukocytes derived from patients with FLT3-ITD-positive AML. This study included patients diagnosed with AML at Tokyo Medical and Dental University Hospital between January 2018 and July 2024. Both treatments blocked downstream FLT3 pathway events, with the effects potentiated by USP14 knockdown. Both treatments inhibited FLT3 deubiquitination via K48 and disrupted translation initiation via 4EBP1, a downstream FLT3 target. FLT3 was downregulated in the leukemic cells, with the associated activation of stress-related MAP kinase pathways and increased NF-E2-related factor 2. Furthermore, the overexpression of B-cell lymphoma-extra-large and myeloid cell leukemia-1 prevented the cell death caused by b-AP15 and AUR. These results suggest that inhibiting USP14/UCHL5, which involves multiple regulatory mechanisms, is a promising target for novel therapies for treatment-resistant FLT3-ITD-positive AML. Full article
(This article belongs to the Special Issue Molecular Mechanism of Leukemogenesis)
Show Figures

Figure 1

Back to TopTop